CHDI Foundation is exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of individuals with HD. To prioritize where our resources will be most effective in HD therapeutic development, we have organized our preclinical research programs into three interconnected units that focus on what we consider the most promising therapeutic areas and the means to pharmacologically interrogate them; namely lowering huntingtin, handling and repair mechanisms related to recently identified mo...